Researchers have unveiled a groundbreaking medication that targets a cholesterol-like particle linked to heart attacks and strokes. Many people might not realize that lipoprotein(a), or Lp(a), which circulates in their bloodstream, poses a significant health risk. Unfortunately, there’s no way to lower elevated Lp(a) levels through lifestyle adjustments, making this discovery particularly noteworthy.
The new drug, lepodisiran, developed by Eli Lilly, effectively “silences” the gene responsible for producing Lp(a). This breakthrough was highlighted in a study led by the Cleveland Clinic and published in The New England Journal of Medicine. Unlike LDL, the “bad cholesterol” we often hear about, Lp(a) is more prone to causing plaque and clots in arteries, posing a unique challenge for heart health.
Dr. Deepak L. Bhatt from Mount Sinai Fuster Heart Hospital explained that Lp(a) is largely determined by genetics. Unlike LDL cholesterol, which can be influenced by various factors, Lp(a) levels remain constant throughout life. This genetic component means lifestyle changes like diet and exercise won’t affect Lp(a) levels, unlike LDL, which can be managed with statins and other medications.
This study involved 320 participants from various countries, including the U.S., China, and Germany, between November 2022 and April 2023. Participants received either a placebo or one or two doses of lepodisiran. The average Lp(a) level in the trial was significantly higher than normal, highlighting the need for effective treatment.
Remarkably, a single high-dose injection of lepodisiran resulted in nearly a 100% reduction in Lp(a) levels after six months. Those who received a second dose maintained this reduction for a year. In essence, the medication virtually eliminated Lp(a) from the bloodstream, offering hope for those at risk due to high Lp(a) levels.
Despite the promising results, the study had limitations. There were no major safety concerns, but some participants experienced mild reactions at the injection site. Additionally, the trial had a limited number of Black participants, a group that research shows has higher Lp(a) levels. Efforts are underway to address this in the next phase of trials.
Experts emphasize the need for further research to determine if reducing Lp(a) levels translates into fewer heart attacks and strokes. A larger phase 3 clinical trial is already in progress to explore this possibility. The European Society of Cardiology and the National Lipid Association encourage adults to check their Lp(a) levels for better heart health insights.
Dr. Bhatt highlighted the importance of knowing one’s Lp(a) levels, as they remain constant throughout life. Unlike traditional cholesterol checks, Lp(a) only needs to be measured once. This early knowledge can guide lifestyle choices to manage heart health risks effectively.
For further information on health topics, readers can visit Fox News Health. Understanding one’s genetic predispositions can empower individuals to take proactive steps toward maintaining heart health.
